Haemonetics Corporation $HAE Stake Raised by Invenomic Capital Management LP

Invenomic Capital Management LP raised its holdings in Haemonetics Corporation (NYSE:HAE) by 1,691.5% in the third quarter, Holdings Channel.com reports. The fund owned 498,317 shares of the medical instruments supplier’s stock after acquiring an additional 470,502 shares during the period. Haemonetics comprises 1.2% of Invenomic Capital Management LP’s portfolio, making the stock its 21st biggest holding. Invenomic Capital Management LP’s holdings in Haemonetics were worth $24,288,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in HAE. EverSource Wealth Advisors LLC raised its holdings in shares of Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 396 shares in the last quarter. Versant Capital Management Inc grew its position in Haemonetics by 216.4% in the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 567 shares during the last quarter. Byrne Asset Management LLC bought a new position in shares of Haemonetics in the third quarter valued at $42,000. Hantz Financial Services Inc. lifted its position in shares of Haemonetics by 792.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,124 shares of the medical instruments supplier’s stock valued at $55,000 after acquiring an additional 998 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of Haemonetics during the 2nd quarter worth $64,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on HAE shares. BTIG Research reaffirmed a “buy” rating and set a $88.00 target price on shares of Haemonetics in a research report on Friday, February 6th. Mizuho cut their price target on shares of Haemonetics from $90.00 to $80.00 and set an “outperform” rating on the stock in a report on Friday, February 6th. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. CJS Securities raised Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. Finally, Barrington Research set a $94.00 price objective on Haemonetics in a research report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $83.89.

Haemonetics Price Performance

HAE opened at $59.93 on Monday. The stock has a fifty day moving average price of $66.67 and a 200 day moving average price of $64.79. The company has a current ratio of 1.75, a quick ratio of 1.15 and a debt-to-equity ratio of 1.01. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32. The stock has a market cap of $2.78 billion, a price-to-earnings ratio of 16.51, a PEG ratio of 1.25 and a beta of 0.28.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. The company had revenue of $338.97 million during the quarter, compared to the consensus estimate of $331.90 million. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The business’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period last year, the business earned $1.19 EPS. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Analysts forecast that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.